Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IMA402 and checkpoint inhibitor

Preclinical

IImmatics Biotechnologies GmbH

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Refractory CancerRecruiting

Refractory CancerPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Refractory Cancer

NCT05958121

Clinical

Trials by Indication[1]

Refractory Cancer1 trial

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors

Recruiting·IImmatics Biotechnologies GmbH·Preclinical·NCT05958121·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IMA402 and checkpoint inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IMA402 and checkpoint inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Immatics Biotechnologies GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: IImmatics Biotechnologies GmbH

Related News